{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:22Z","timestamp":1792783462401,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of P\u00e9cs","id":[{"id":"https:\/\/ror.org\/037b5pv06","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01038-6","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:53:38Z","timestamp":1789739618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concentration-to-Dose Ratio Differences Between Once-Daily Tacrolimus Formulations: A Five-Year Real-World Pharmacokinetic Study in Kidney Transplantation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7244-2291","authenticated-orcid":false,"given":"Adam","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Borbasne Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoly","family":"Kalmar Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szakaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"3","key":"1038_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100842","volume":"38","author":"W Xie","year":"2024","unstructured":"Xie W, Fan S, Liu R, et al. Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation. Transplant Rev (Orlando). 2024;38(3):100842. https:\/\/doi.org\/10.1016\/j.trre.2024.100842.","journal-title":"Transplant Rev (Orlando)"},{"issue":"8","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/tri.12674","volume":"29","author":"S Caillard","year":"2016","unstructured":"Caillard S, Moulin B, Buron F, et al. Advagraf(\u00ae), a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transpl Int. 2016;29(8):860\u20139. https:\/\/doi.org\/10.1111\/tri.12674.","journal-title":"Transpl Int"},{"issue":"12","key":"1038_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1111\/ajt.12955","volume":"14","author":"K Budde","year":"2014","unstructured":"Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial. Am J Transplant. 2014;14(12):2796\u2013806. https:\/\/doi.org\/10.1111\/ajt.12955.","journal-title":"Am J Transplant"},{"key":"1038_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.11571","volume":"37","author":"M Giral","year":"2024","unstructured":"Giral M, Grimbert P, Morin B, et al. Impact of switching from immediate- or prolonged-release to once-daily extended-release tacrolimus (LCPT) on tremor in stable kidney transplant recipients: the observational ELIT study. Transpl Int. 2024;37:11571. https:\/\/doi.org\/10.3389\/ti.2024.11571.","journal-title":"Transpl Int"},{"issue":"2","key":"1038_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.transproceed.2013.11.139","volume":"46","author":"J Uchida","year":"2014","unstructured":"Uchida J, Iwai T, Kabei K, et al. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. Transplant Proc. 2014;46(2):532\u20136. https:\/\/doi.org\/10.1016\/j.transproceed.2013.11.139.","journal-title":"Transplant Proc"},{"issue":"Suppl 1","key":"1038_CR6","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1093\/ndt\/gfg1029","volume":"18","author":"NA Undre","year":"2003","unstructured":"Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003;18(Suppl 1):i12\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfg1029.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1038_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","volume":"25","author":"T van Gelder","year":"2002","unstructured":"van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25(10):707\u201312. https:\/\/doi.org\/10.2165\/00002018-200225100-00003.","journal-title":"Drug Saf"},{"issue":"4","key":"1038_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","volume":"40","author":"PE Wallemacq","year":"2001","unstructured":"Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 2001;40(4):283\u201395. https:\/\/doi.org\/10.2165\/00003088-200140040-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1038_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","volume":"53","author":"DA Hesselink","year":"2014","unstructured":"Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123\u201339. https:\/\/doi.org\/10.1007\/s40262-013-0120-3.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1038_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3892\/etm.2015.2598","volume":"10","author":"NZ Stefanovi\u0107","year":"2015","unstructured":"Stefanovi\u0107 NZ, Cvetkovi\u0107 TP, Jevtovi\u0107-Stoimenov TM, Ignjatovi\u0107 AM, Paunovi\u0107 GJ, Veli\u010dkovi\u0107 RM. Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: effects on tacrolimus exposure and kidney function. Exp Ther Med. 2015;10(3):1149\u201356. https:\/\/doi.org\/10.3892\/etm.2015.2598.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1038_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.transproceed.2013.11.023","volume":"46","author":"Y Hattori","year":"2014","unstructured":"Hattori Y, Tanaka H, Teranishi J, et al. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus. Transplant Proc. 2014;46(2):570\u20133. https:\/\/doi.org\/10.1016\/j.transproceed.2013.11.023.","journal-title":"Transplant Proc"},{"issue":"11","key":"1038_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1440-1681.2006.04492.x","volume":"33","author":"YF Hu","year":"2006","unstructured":"Hu YF, Qiu W, Liu ZQ, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol. 2006;33(11):1093\u20138. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04492.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"13","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5414\/CNP88FX25","volume":"88","author":"G Mlin\u0161ek","year":"2017","unstructured":"Mlin\u0161ek G, Dol\u017ean V, Gori\u010dar K, Buturovi\u0107-Ponikvar J, Arnol M. The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients. Clin Nephrol. 2017;88(13):115\u20138. https:\/\/doi.org\/10.5414\/CNP88FX25.","journal-title":"Clin Nephrol"},{"issue":"1","key":"1038_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19\u201324. https:\/\/doi.org\/10.1002\/cpt.113.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1038_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/jcph.2249","volume":"63","author":"E Tillman","year":"2023","unstructured":"Tillman E, Nikirk MG, Chen J, et al. Implementation of clinical cytochrome P450 3A genotyping for tacrolimus dosing in a large kidney transplant program. J Clin Pharmacol. 2023;63(8):961\u20137. https:\/\/doi.org\/10.1002\/jcph.2249.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1038_CR16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/s0041-1345(02)03002-6","volume":"34","author":"K Uchida","year":"2002","unstructured":"Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc. 2002;34(5):1736\u20137. https:\/\/doi.org\/10.1016\/s0041-1345(02)03002-6.","journal-title":"Transplant Proc"},{"issue":"4","key":"1038_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/1389200219666180101104159","volume":"19","author":"K Schutte-Nutgen","year":"2018","unstructured":"Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus\u2014pharmacokinetic considerations for clinicians. Curr Drug Metab. 2018;19(4):342\u201350. https:\/\/doi.org\/10.2174\/1389200219666180101104159.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"1038_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","volume":"44","author":"Y Bentata","year":"2020","unstructured":"Bentata Y. Tacrolimus: 20\u00a0years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140\u201352. https:\/\/doi.org\/10.1111\/aor.13551.","journal-title":"Artif Organs"},{"issue":"10","key":"1038_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1038_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5500\/wjt.v7.i1.26","volume":"7","author":"G Th\u00f6lking","year":"2017","unstructured":"Th\u00f6lking G, Gerth HU, Schuette-Nuetgen K, Reuter S. Influence of tacrolimus metabolism rate on renal function after solid organ transplantation. World J Transplant. 2017;7(1):26\u201333. https:\/\/doi.org\/10.5500\/wjt.v7.i1.26.","journal-title":"World J Transplant"},{"key":"1038_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep32273","volume":"6","author":"G Th\u00f6lking","year":"2016","unstructured":"Th\u00f6lking G, Schmidt C, Koch R, et al. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016;6:32273. https:\/\/doi.org\/10.1038\/srep32273.","journal-title":"Sci Rep"},{"issue":"10","key":"1038_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101586","volume":"8","author":"G Th\u00f6lking","year":"2019","unstructured":"Th\u00f6lking G, Sch\u00fctte-N\u00fctgen K, Schmitz J, et al. A low tacrolimus concentration\/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. J Clin Med. 2019;8(10):1586. https:\/\/doi.org\/10.3390\/jcm8101586.","journal-title":"J Clin Med"},{"issue":"3","key":"1038_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/tri.13356","volume":"32","author":"EJ Egeland","year":"2019","unstructured":"Egeland EJ, Reisaeter AV, Robertsen I, et al. High tacrolimus clearance\u2014a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. Transpl Int. 2019;32(3):257\u201369. https:\/\/doi.org\/10.1111\/tri.13356.","journal-title":"Transpl Int"},{"issue":"1","key":"1038_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/tpj.2014.38","volume":"15","author":"L Rojas","year":"2015","unstructured":"Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15(1):38\u201348. https:\/\/doi.org\/10.1038\/tpj.2014.38.","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"1038_CR25","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1016\/j.transproceed.2019.08.030","volume":"51","author":"E Kwiatkowska","year":"2019","unstructured":"Kwiatkowska E, Kwiatkowski S, Wahler F, et al. C\/D ratio in long-term renal function. Transplant Proc. 2019;51(10):3265\u201370. https:\/\/doi.org\/10.1016\/j.transproceed.2019.08.030.","journal-title":"Transplant Proc"},{"issue":"6","key":"1038_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","volume":"104","author":"T Jouve","year":"2020","unstructured":"Jouve T, Fonrose X, Noble J, et al. The TOMATO study (Tacrolimus metabolization in kidney transplantation): impact of the concentration-dose ratio on death-censored graft survival. Transplantation. 2020;104(6):1263\u201371. https:\/\/doi.org\/10.1097\/TP.0000000000002920.","journal-title":"Transplantation"},{"issue":"6","key":"1038_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70197","volume":"39","author":"R Nogueiras-\u00c1lvarez","year":"2025","unstructured":"Nogueiras-\u00c1lvarez R, Garc\u00eda-Saiz MDM. Tacrolimus intrapatient variability as a biomarker in solid organ transplantation. Clin Transplant. 2025;39(6):e70197. https:\/\/doi.org\/10.1111\/ctr.70197.","journal-title":"Clin Transplant"},{"issue":"1","key":"1038_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cpt.2220","volume":"110","author":"P Fontova","year":"2021","unstructured":"Fontova P, Colom H, Rigo-Bonnin R, et al. Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients. Clin Pharmacol Ther. 2021;110(1):238\u201347. https:\/\/doi.org\/10.1002\/cpt.2220.","journal-title":"Clin Pharmacol Ther"},{"key":"1038_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01142","volume":"11","author":"T van Gelder","year":"2020","unstructured":"van Gelder T, Meziyerh S, Swen JJ, et al. The clinical impact of the C0\/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142. https:\/\/doi.org\/10.3389\/fphar.2020.01142.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1038_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00228-011-1163-0","volume":"68","author":"P Stratta","year":"2012","unstructured":"Stratta P, Quaglia M, Cena T, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68(5):671\u201380. https:\/\/doi.org\/10.1007\/s00228-011-1163-0.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01038-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:53:40Z","timestamp":1789739620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":30,"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01038-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest regarding this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Research Ethics Committee (approval no. 4816).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived because of the retrospective nature of the study and the use of anonymized clinical data, in accordance with institutional and national regulations.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors jointly contributed to the drafting and critical revision of the manuscript, and all approved the final version for submission.","order":5,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request. The statistical code used for the analyses is available from the corresponding author on reasonable request. No organs were procured from executed prisoners or other institutionalized individuals. All donor organs were obtained in accordance with national legislation and ethical standards. Deceased-donor kidneys were allocated through the Eurotransplant International Foundation according to standard allocation procedures.","order":6,"name":"Ethics","label":"Availability of Data and Material and Statistical Code","group":{"name":"EthicsHeading","label":"Declarations"}}]}}